Novaquest Capital Management, L.L.C.
SEC-registered
Private Fund Manager · Mid-sized ($1B–$10B)
CRD 160359
· SEC file 801-73992
·
· WWW.NOVAQUEST.COM
☆ Save with Pro
ADV data as of Mar 31, 2026
- Regulatory AUM
- $1.5B
- Discretionary
- $1.5B
- Clients
- 14
- Avg AUM / client
- $106M
- Accounts
- 14
- Employees
- 18
AUM over time
$398M
$2.8B
Dec 2011
Dec 2025
Annual snapshots from Form ADV filings · as of Mar 31, 2026
Who they serve
| Client type | Clients | AUM | % of AUM |
|---|---|---|---|
| Pooled investment vehicles (non-investment companies) | 14 | $1.5B | 100.0% |
Private funds (38)
View all →Reported in Form ADV Section 7.B.(1), filing of Oct 2024 · $3.2B combined gross assets
| Fund | Type | Domicile | Gross assets | Owners |
|---|---|---|---|---|
| Novaquest Pharma Opportunities Fund V, L.P. | Private Equity Fund | Cayman Islands | $656M | 18 |
| Novaquest Pharma Opportunities Fund V (Delaware), L.P. master | Private Equity Fund | Delaware | $380M | 6 |
| Novaquest Co Investment Fund Viii, L.P. | Private Equity Fund | Delaware | $228M | 51 |
| Novaquest Pharma Opportunities Fund Iv, L.P. | Private Equity Fund | Cayman Islands | $181M | 36 |
| Novaquest Animal Health Opportunities Fund Aggregator, L.P. | Private Equity Fund | Cayman Islands | $132M | 2 |
| Nq Project Pharaoh, L.P. | Private Equity Fund | Delaware | $130M | 20 |
| Novaquest Pharma Opportunities Fund Iv Aggregator, L.P. | Private Equity Fund | Cayman Islands | $118M | 2 |
| Novaquest Animal Health Opportunities Fund (Delaware), L.P. | Private Equity Fund | Delaware | $117M | 1 |
| Nqp Spv Ii, L.P. | Private Equity Fund | Cayman Islands | $95.0M | 20 |
| Novaquest Pharma Opportunities Fund Vi, L.P. | Private Equity Fund | Cayman Islands | $88.1M | 2 |
| Nqp Aiv I, L.P. | Private Equity Fund | Cayman Islands | $87.8M | 6 |
| Nq Project Bridgeton, L.P. | Private Equity Fund | Delaware | $85.6M | 20 |
| Nq Project Glasgow, Ltd. | Private Equity Fund | Cayman Islands | $83.9M | 20 |
| Novaquest Co Investment Fund Xvi, L.P. | Private Equity Fund | Delaware | $72.8M | 20 |
| Novaquest Pharma Opportunities Fund Iv (Co Invest), L.P. | Private Equity Fund | Cayman Islands | $67.2M | 1 |
People (9)
| Name | Role / title | Credentials | With firm since | Ownership |
|---|---|---|---|---|
| Brown, Ernest, Gerald | Management Committee Member | Nov 2010 (16y) | Less than 5% | |
| Hester, Robert, Wayne | Member, Chief Financial Officer, Executive Vice President | Nov 2010 (16y) | Less than 5% | |
| Mills, Bryan, Edwards | Member, Chief Administrative Officer, Management Committee Member | Jan 2020 (7y) | Less than 5% | |
| Jordan, Patrick, Brooks | Member, Managing Partner, Chief Operating Officer, Management Committee Member | Apr 2021 (5y) | Less than 5% | |
| Gillings, Dennis, Barry | Shareholder | Jan 2022 (5y) | ≈ 28.13% – 75% via Gf Management Holdings Inc. | |
| Gillings, Mireille | Shareholder | Jan 2022 (5y) | ≈ 9.38% – 37.5% via Gf Management Holdings Inc. | |
| Bologna, Michael, James | Member, Chief Investment Officer, Management Committee Member | Jul 2023 (3y) | Less than 5% | |
| Holden, Devin, Weiss | Chief Compliance Officer | Jan 2024 (3y) | Less than 5% | |
| Oshiba, Yoshitaka | Management Committee Member | Aug 2024 (2y) | Less than 5% |
Entity owners (Schedule A/B)
| Entity | Title / status | Since | Sch. | Ownership |
|---|---|---|---|---|
| Pharmabio Development Inc. | Member | Nov 2010 | A | 50% – 75% |
| Mbk Pharmapartnering, Inc. | Member | Nov 2010 | A | 10% – 25% |
| Mitsui & Co., Ltd. | Shareholder | Nov 2010 | B | ≈ 7.5% – 25% via Mbk Pharmapartnering, Inc. |
| Gf Management Holdings Inc. | Shareholder | Jan 2022 | B | ≈ 37.5% – 75% via Pharmabio Development Inc. |
Undisclosed: 0% – 40% of the firm is not attributable from the filed Schedule A bands.
Estimated effective ownership (look-through of filed bands):
- Gillings, Dennis, Barry: 75% – 100% of Gf Management Holdings Inc. × 75% – 100% of Pharmabio Development Inc. × 50% – 75% direct ≈ 28.13% – 75% of the firm
- Gillings, Mireille: 25% – 50% of Gf Management Holdings Inc. × 75% – 100% of Pharmabio Development Inc. × 50% – 75% direct ≈ 9.38% – 37.5% of the firm
- Mitsui & Co., Ltd.: 75% – 100% of Mbk Pharmapartnering, Inc. × 10% – 25% direct ≈ 7.5% – 25% of the firm
- Gf Management Holdings Inc.: 75% – 100% of Pharmabio Development Inc. × 50% – 75% direct ≈ 37.5% – 75% of the firm
Roster from the IAPD representatives feed; ownership and acquisition dates from Form ADV Schedule A/B. "Since" is the earliest filed registration or acquisition date.
Private funds (38, $3.2B gross assets)
| Fund | Type | Gross assets | Min. investment | Owners |
|---|---|---|---|---|
| Novaquest Pharma Opportunities Fund V, L.P. | Private Equity Fund | $656M | $25.0M | 18 |
| Novaquest Pharma Opportunities Fund V (Delaware), L.P. | Private Equity Fund | $380M | $25.0M | 6 |
| Novaquest Co Investment Fund Viii, L.P. | Private Equity Fund | $228M | $25.0M | 51 |
| Novaquest Pharma Opportunities Fund Iv, L.P. | Private Equity Fund | $181M | $25.0M | 36 |
| Novaquest Animal Health Opportunities Fund Aggregator, L.P. | Private Equity Fund | $132M | $5.0M | 2 |
| Nq Project Pharaoh, L.P. | Private Equity Fund | $130M | $25.0M | 20 |
| Novaquest Pharma Opportunities Fund Iv Aggregator, L.P. | Private Equity Fund | $118M | $25.0M | 2 |
| Novaquest Animal Health Opportunities Fund (Delaware), L.P. | Private Equity Fund | $117M | $5.0M | 1 |
| Nqp Spv Ii, L.P. | Private Equity Fund | $95.0M | $25.0M | 20 |
| Novaquest Pharma Opportunities Fund Vi, L.P. | Private Equity Fund | $88.1M | $10.0M | 2 |
| Nqp Aiv I, L.P. | Private Equity Fund | $87.8M | $25.0M | 6 |
| Nq Project Bridgeton, L.P. | Private Equity Fund | $85.6M | $25.0M | 20 |
| Nq Project Glasgow, Ltd. | Private Equity Fund | $83.9M | $25.0M | 20 |
| Novaquest Co Investment Fund Xvi, L.P. | Private Equity Fund | $72.8M | $25.0M | 20 |
| Novaquest Pharma Opportunities Fund Iv (Co Invest), L.P. | Private Equity Fund | $67.2M | $25.0M | 1 |
| Novaquest Co Investment Fund Ix, L.P. | Private Equity Fund | $66.7M | $25.0M | 20 |
| Nqp Spv I, L.P. | Private Equity Fund | $63.1M | $25.0M | 51 |
| Novaquest Co Investment Fund Xviii, L.P. | Private Equity Fund | $54.1M | $25.0M | 20 |
| Nq Project Phoebus, L.P. | Private Equity Fund | $53.2M | $25.0M | 20 |
| Novaquest Co Investment Fund Vii, L.P. | Private Equity Fund | $51.9M | $25.0M | 51 |
| Novaquest Co Investment Fund Xvii, L.P. | Private Equity Fund | $50.6M | $25.0M | 51 |
| Novaquest Pharma Opportunities Fund Iii, L.P. | Private Equity Fund | $48.1M | $10.0M | 14 |
| Nq Cove Aggregator, L.P. | Private Equity Fund | $46.6M | $0 | 2 |
| Nq Project Sampson, L.P. | Private Equity Fund | $40.9M | $25.0M | 51 |
| Novaquest Pharma Opportunities Fund Iii Aggregator, L.P. | Private Equity Fund | $31.7M | $10.0M | 1 |
Top 25 of 38 funds by gross assets · all funds
From Form ADV Section 7.B private fund reporting.
Documents (1 archived)
| Form | Period | Size | |
|---|---|---|---|
| Form ADV (full filing) | 03/31/2026 | 4.19 MB | View · PDF · Source ↗ |
Archived copies of the firm's regulatory filings, versioned by content hash.
Disciplinary disclosures
No disciplinary events reported on the firm's latest Form ADV filing.
How they charge
- • Percentage of assets under management
- • Performance-based fees
Services
- • Portfolio management for pooled investment vehicles
Custody
Firm reports having custody of client funds or securities (Item 9.A).
No custodian data reported or mined yet.
Source
All data on this page comes from this firm's Form ADV filings, reproduced without modification. Latest filing: Mar 31, 2026.
View current Form ADV (SEC/IAPD) ↗